# Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

> **NCT00774202** · PHASE2,PHASE3 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 17 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** Rituxan, Cyclophosphamide, Vincristine, Prednisone
- **DRUG:** Higher Dose of Rituximab

## Key facts

- **NCT ID:** NCT00774202
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774202, "Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00774202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*